Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
18 sept. 2023 08h00 HE
|
Medigene AG
Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs
01 juin 2023 07h00 HE
|
Medigene AG
Medigene is building a broad KRAS library consisting of multiple T cell receptors (TCRs) targeting multiple KRAS mutations and multiple HLAs, covering large patient populations suffering from...
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
08 mars 2022 02h00 HE
|
VAXIMM AG
VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen fieldNEC OncoImmunity to initiate first clinical trial...
Neoantigens Market Size ($10,54,783.54 Thousand by 2028) Growth Forecast at 31.2% CAGR During 2023 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
07 oct. 2021 10h16 HE
|
The Insight Partners
New York, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Neoantigens Market: Key InsightsAccording to our new research study on “Neoantigens Market to 2028 – Global Analysis and Forecast – by Treatment and...
VAXIMM, 다수의 해외 과학 및 산업 이벤트 참가 예정
27 mai 2021 03h30 HE
|
VAXIMM AG
스위스 바젤/독일 만하임, May 27, 2021 (GLOBE NEWSWIRE) -- 스위스/독일 바이오테크 회사인 VAXIMM AG가 다수의 해외 과학 및 산업 이벤트 참석 계획을 발표했다. 자사는 환자의 세포독성 T세포 활성화를 통해 다양한 암 관련 항원을 표적으로 하는 경구용 플러그 앤 플레이(plug and play) DNA 백신 투여 기술...
VAXIMM to Attend International Scientific and Industry Events
27 mai 2021 03h30 HE
|
VAXIMM AG
BASEL, Switzerland and MANNHEIM, Germany, May 27, 2021 (GLOBE NEWSWIRE) -- VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to...
Aldevron announces GMP gene synthesis service to support neoantigen-based oncology research and other applications
02 oct. 2019 11h10 HE
|
Aldevron
Fargo, ND, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aldevron has added GMP gene synthesis to its array of services. This expanded capability will be used primarily to support Aldevron’s clients who require...
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma
13 févr. 2019 03h00 HE
|
Achilles Therapeutics
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK 13 February...